Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

COVID-19 cases rising due to increased indoor transmission

While there has been a recent increase in daily confirmed cases in Europe, coinciding with the start of the autumn and winter weather, there is not yet enough evidence to suggest that COVID-19 will become a seasonal virus, says GlobalData, a leading data and analytics company. Bishal Bhandari at GlobalData comments: “COVID-19 cases have started to […]
Read more

Pfizer and BioNTech’s final Phase III COVID-19 vaccine analysis could decrease by 10 points from interim 90% data; vaccine could require testing to screen prior infection but rationale still theoretical

With Pfizer and BioNTech announcing that a Phase III trial investigating the BNT162b2 vaccine to be 90% effective in preventing symptomatic COVID-19 in participants without evidence of prior infection; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:   “The final Phase III efficacy analysis of Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 […]
Read more

Hyundai bets big on SUVs for North America

Following the news that the Hyundai plans to launch twelve new SUVs for the North American market by 2021; Bakar Sadik Agwan, Senior Automotive Consulting Analyst at GlobalData, a leading data and analytics company, offers his view: “The launch of new models by 2021 is anticipated to attract further major volume sales for Hyundai in […]
Read more

Pharma was forced to shuffle technology investment priorities due to COVID-19

COVID-19 has been a wake-up call for pharma companies to rethink their operations and customer access. Embracing digital transformation will have an important role to play in ensuring that the industry overcomes existing and long-term business challenges, seizes opportunities and continues to thrive in challenging business landscape, says GlobalData, a leading data and analytics company. […]
Read more

Biden presidency to ease region’s China dilemma

Following the news that the US Democratic Party candidate Joe Biden looks to have won the 2020 US Presidential Election after a tight race against Republican incumbent Donald Trump; Colin Foreman, Deputy Editor at MEED, part of GlobalData, offers his view: “The election of Joe Biden as the next US president could result in a softening […]
Read more

Biden win could test oil markets

Following the recent news that the US Democratic Party candidate, Joe Biden, looks to have won the 2020 US Presidential Election after a tight race against Republican incumbent, Donald Trump; Indrajit Sen, Oil & Gas Editor at MEED, part of GlobalData, offers their view: “Joe Biden’s stated intention to lift sanctions on Iran could mar efforts […]
Read more

Demand from packaging and healthcare segments to help polyolefins market stay afloat amid COVID-19

The global polyolefins market is expected to decline in 2020 due to weaker end-market demand from applications such as construction, automotive and industrial. However, the pandemic-driven feeble demand is partially offset by strong and increased demand from sectors such as packaging, fast-moving consumer goods (FMCG), and healthcare, says GlobalData, a leading data and analytics company. When asked about the weak market demand for polyolefins, David […]
Read more

Current global contract manufacturing will not keep up with global COVID-19 vaccine demand

A significant proportion of vaccine developers are smaller companies that lack the capacity and funds to manufacture their vaccines in-house. However, there is also simply not enough contract manufacturing capacity worldwide to cope with commercial COVID-19 vaccine demand, says GlobalData, a leading data and analytics company. Adam Bradbury, PharmSource Analyst at GlobalData, comments: “According to GlobalData’s Service Provider Database, there are 195 contract facilities at 123 companies offering vaccine active pharmaceutical ingredient (API) manufacture. It is difficult to […]
Read more

While Pfizer and BioNTech’s ‘90% efficacy’ data raises expectations for mRNA vaccines, it will take many more months for key questions to be answered

Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Experts initially assumed that first iterations of a COVID-19 vaccine would show efficacies not much better than common seasonal influenza vaccines, which are usually only 40–60% effective. At a reported 90%, Pfizer and BioNTech’s […]
Read more

EU Horizon 2020 research and innovation program invested almost €6M ($7.1M) for COVID-19

In response to the COVID-19 pandemic, Horizon 2020 (H2020), the EU’s biggest research and innovation program, invested almost €6M ($7.1M) for COVID-19 related research and drug development in April 2020. This demonstrates how granting agencies have reacted quickly to prioritizing COVID-19 research, says GlobalData, a leading data and analytics company. Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments: “All […]
Read more

Rapid adoption of AI could cause problems due to biased data

The COVID-19 pandemic has caused rapid adoption, integration and development of artificial intelligence (AI) and machine learning (ML) into the healthcare industry. AI is being widely used for early detection of COVID-19 and contact tracing, as well as helps support the the development and research of vaccines. According to data  and analytics company GlobalData forecasts, […]
Read more

NYC experiencing second rise in COVID-19

New York City has reported a significant rise in the number of COVID-19 cases for the first time since mid-June, prompting fears of a resurgence of the disease in the area in the last two weeks, and there has been an average of more than 1,300 daily new cases for the last 13 days in […]
Read more

Lack of skills and talents poses the biggest challenge to digital transformation in pharmaceutical industry

COVID-19 is set to be a major catalyst for the pharmaceutical industry. The rush to adapt to new social distancing and lockdown norms has led to a hurried digital transformation, leaving many organizations struggling to bridge the digital skills gap, says GlobalData, a leading data and analytics company. GlobalData’s latest report, Digital Transformation and Emerging Technology […]
Read more

COVID-19 is driving more supplier redundancy

Contract development and manufacturing organizations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in the supply chain, says GlobalData, a leading data and analytics company. Peter Shapiro, PharmSource Senior Director of Drugs and Business Fundamentals at GlobalData, comments: “Pharma companies may try to reduce […]
Read more

FDA likely to approve Biogen’s Aducanumab after its review

Following the release of FDA documents today noting support for the safety and efficacy of Biogen’s treatment for Alzheimer’s Disease (AD), aducanumab, it is looking very likely that the drug will become the first new AD therapy to be approved in 17 years. If it is approved, the drug could be in the market by […]
Read more

Morgan Stanley and Evercore were top M&A financial advisers by value and volume in oil and gas sector for Q1-Q3 2020

Morgan Stanley and Evercore have emerged as the top mergers and acquisitions (M&A) financial advisers in the oil and gas sector for Q1-Q3 2020 by value and volume, respectively. A total of 1,115 M&A deals were announced in oil and gas sector during the period, according to GlobalData, a leading data and analytics company. According to GlobalData’s M&A report, ‘Global and Oil & Gas M&A Report Financial Adviser League Tables Q1-Q3 2020’, […]
Read more
1 … 4 5 6 7 8 … 15